🇺🇸 Adalimumab, solution for injection in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 10

Most-reported reactions

1. Abdominal Discomfort — 1 report (10%)
2. Ankylosing Spondylitis — 1 report (10%)
3. Blindness Unilateral — 1 report (10%)
4. Blood Iron Decreased — 1 report (10%)
5. Chronic Gastritis — 1 report (10%)
6. Confusional State — 1 report (10%)
7. Crohn^S Disease — 1 report (10%)
8. Diarrhoea — 1 report (10%)
9. Diarrhoea Haemorrhagic — 1 report (10%)
10. Drug Ineffective — 1 report (10%)

Source database →

Frequently asked questions

Is Adalimumab, solution for injection approved in United States?

Adalimumab, solution for injection does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Adalimumab, solution for injection in United States?

GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.